CPhI Online

- Market News

Recipharm signs up for aseptic fill-finish manufacturing of Moderna COVID-19 vaccine

24 Nov 2020

Recipharm will provide aseptic fill-finish manufacturing at its Monts, France facility. (Image source: Recipharm)

The CDMO is already making certain investments to enable technology transfer and scale-up to commence imminently.

A week after the release of Moderna's successful COVID-19 vaccine candidate efficacy results, Recipharm has signed a letter of intent with US-based biotech company, to formulate, fill and finish mRNA-1273.

The contract development and manufacturing organisation (CDMO) will perform the activity at its drug product manufacturing facility located in Monts, France.

Recipharm has reserved capacity to support the anticipated demand for the vaccine and is already in the process of recruiting additional staff and making certain investments to enable technology transfer and scale-up to commence imminently.

In a press release, Thomas Eldered, CEO of Recipharm, said that they anticipate the final agreement will be finalised during December.

Last Tuesday — the day after announcing their headline trial results — Moderna struck a supply agreement with the UK government to supply its COVID-19 vaccine candidate, beginning in March 2021 if it is approved for use by UK regulatory authorities.

Moderna continues to scale up its global manufacturing to be able to deliver approximately 500 million doses per year and possibly up to 1 billion doses per year, beginning in 2021. The Company is also working with its strategic manufacturing partners, Lonza of Switzerland and ROVI of Spain, for manufacturing and fill-finish outside of the US.

The European Medicines Agency (EMA) human medicines committee (CHMP) has already started a rolling review of mRNA-1273.

Read More

Related Content